Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This randomized phase II study compare survival outcomes and toxicity of two chemotherapy
regimens (etoposide plus lobaplatin or etoposide plus cisplatin) in combination with
concurrent thoracic radiation therapy (TRT) for limited stage small cell lung cancer.